Affiliation:
1. Center of Pharmaceutical Analytics, 8, Simferopolskiy bul, Moscow 117246, Russia
2. RUDN University, 6 Miklukho-Maklaya St., Moscow 117149, Russia
3. PROMOMED RUS, 13/1 Prospekt Mira, Moscow 129090, Russia
Abstract
Molnupiravir is an antiviral drug against viral RNA polymerase activity approved by the FDA for the treatment of COVID-19, which is metabolized to β-D-N4-hydroxycytidine (NHC) in human blood plasma. A novel method was developed and validated for quantifying NHC in human plasma within the analytical range of 10–10,000 ng/mL using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) to support pharmacokinetics studies. For sample preparation, the method of protein precipitation by acetonitrile was used, with promethazine as an internal standard. Chromatographic separation was carried out on a Shim-pack GWS C18 (150 mm × 4.6 mm, 5 μm) column in a gradient elution mode. A 0.1% formic acid solution in water with 0.08% ammonia solution (eluent A, v/v) and 0.1% formic acid solution in methanol with 0.08% ammonia solution mixed with acetonitrile in a 4:1 ratio (eluent B, v/v) were used as a mobile phase. Electrospray ionization (ESI) was used as an ionization source. The developed method was validated in accordance with the Eurasian Economic Union (EAEU) rules, based on the European Medicines Agency (EMA) and Food and Drug Administration (FDA) guidelines for the following parameters and used within the analytical part of the clinical study of molnupiravir drugs: selectivity, suitability of standard sample, matrix effect, calibration curve, accuracy, precision, recovery, lower limit of quantification (LLOQ), carryover, and stability.
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference33 articles.
1. Huang, C., Lu, T.L., and Lin, L. (2023). Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis. Antibiotics, 12.
2. Impact of COVID-19 on the changing patterns of respiratory syncytial virus infections;Garg;Infect. Dis. Rep.,2022
3. (2023, April 11). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/.
4. Development and Validation of HPLC-UV Method for the Determination of Favipiravir in Human Plasma;Komarov;Drug Dev.,2022
5. Simultaneous Determination of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) and Favipiravir in Human Plasma by HPLC-MS/MS;Komarov;Drug Dev.,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献